Mireille Cantarini, BSc, MB, ChB, MRCP, FFPM
Senior Medical Director, Medical Affairs, Oncology
Mireille Cantarini is Vice President and Therapeutic Area Operational Strategy Lead for the Hematology and Oncology Franchise at Worldwide Clinical Trials. Her career in clinical research spans almost two decades and has seen her engaged in clinical studies around the globe, across all phases of study from first-in-human to pivotal registration studies. She is committed to the professional development of physicians within the pharmaceutical industry and has a history of peer-reviewed scientific publications going back to 1987.
ABOUT MIREILLE CANTARINI, BSc, MB, ChB, MRCP, FFPM
Dr. Cantarini has worked in clinical research for more than 18 years. She began her pharmaceutical research career in the AstraZeneca Clinical Pharmacology Unit as a Medical Adviser contributing to clinical pharmacology studies across multiple therapeutic areas, ultimately becoming Medical Director of the Clinical Pharmacology Unit. After this period, she transferred to the Oncology Early Clinical Development organization where she was involved in Phase I/IIb studies across several cancer indications across global locations (including the EU, US, Southeast Asia, Japan, South America, South Africa, and China). During this period, she held the role of Honorary Fellow in the Department of Genomic Medicine at St Mary’s Hospital, working with Professor Gareth Evans who was fundamental in the Phase II studies of olaparib (an AstraZeneca drug) in BRCA-mutated tumors. Most recently, Dr. Cantarini was involved as Executive Medical Director in the osimertinib (indication T790M-positive non-small cell lung cancer (NSCLC)) program, taking the clinical development from first dose-in-human to full regulatory approvals in all major territories (FDA, EMEA, Japan, and China) in four years.
She has been study/project physician for many studies in the oncology area including T790M-positive non-small cell lung cancer (Phase I-III and supporting clinical pharmacology programs, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)); BRAF-mutated melanoma (Phase I-II and supporting clinical pharmacology programs, mitogen-activated protein kinase (MEK) inhibitor); and “all-comer” first-into-human studies (fibroblast growth factor receptor (FGFR) inhibitor, protein kinase B (AKT) inhibitor, second generation MEK inhibitor, second generation EGFR TKI). She has a 30-year record of publications in peer-reviewed journals, including Nature Medicine, New England Journal of Medicine, Journal of Clinical Oncology, and The Lancet Oncology.
Dr. Cantarini holds a BSc from the University of Southampton and a MBChB from Bristol University Medical School.
ASK MIREILLE A QUESTION
EXPLORE OTHER WORLDWIDE EXPERTS
Global Regulatory Strategist
Senior Vice President, Project Management, Cardiovascular, Endocrince & Metabolic and Real World Evidence
Ian Braithwaite, PhD
Senior Vice President, Project Management, Other and Rare Diseases